---
title: "Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations"
date: "2025-02-10 22:46:04"
summary: "CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&amp;D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / **Cosmos Health Inc.** **("Cosmos Health" or the "Company'')** , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations.

Mr. Moraitis brings over 25 years of experience in strategic planning, operations, and business development within the pharmaceutical sector. In his new role, he will be responsible for driving strategic initiatives and optimizing operational processes to support Cosmos Health's mission of delivering innovative pharmaceutical solutions globally.

Throughout his distinguished career, Mr. Moraitis has held key leadership positions at major pharmaceutical companies, including DEMO, MENARINI, the VIANEX Group, and TIKUN OLAM Europe. He has played a pivotal role in shaping industry strategies and driving business growth in the pharmaceutical sector.

In addition, Mr. Moraitis has served as both a leader and board member of several prominent pharmaceutical associations, including AESGP (Association of the European Self-Care Industry), the leading European association representing manufacturers of non-prescription medicines, food supplements, and self-care medical devices; ΕfEX (Hellenic Association of Self-Care Products), the Greek association promoting self-care solutions and OTC healthcare products; SEPTΕDE (Association of Enterprises for Infant Nutrition & Special Dietary Products of Greece), focusing on the regulation and development of infant nutrition and special dietary products; and SAFFE (Hellenic Association of Pharmaceutical Enterprises & Representatives), an influential organization representing pharmaceutical enterprises and their contributions to the Greek market.

Dimitris Moraitis expressed his enthusiasm about joining Cosmos Health: "I am honored to be part of Cosmos, a company dedicated to advancing pharmaceutical innovation. Greg Siokas is a visionary leader with a forward-thinking approach, and I look forward to applying my experience to support the Company's growth strategy and contribute to the development of innovative solutions that enhance patient care worldwide."

**Greg Siokas, CEO of Cosmos Health, stated:** "We are thrilled to welcome Dimitris to our management team. His extensive experience and deep understanding of the pharmaceutical industry make him an invaluable addition. I have absolute confidence in his ability to lead our strategic and operational initiatives as we continue to expand our global footprint."

**About Cosmos Health Inc.**

Cosmos Health Inc. , incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

**Forward-Looking Statements**

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Investor Relations Contact:**

BDG Communications

cosm@bdgcommunications.com

+44 207 0971 653

**SOURCE:** Cosmos Health Inc.

View the original press release on ACCESS Newswire

[Reuters](https://www.tradingview.com/news/reuters.com,2025-02-10:newsml_ACSzly5Xa:0/)
